NCT00753740 2020-06-12Efficacy Study of Maintenance IT-101 Therapy for Ovarian Cancer Patients.Lumos PharmaPhase 2 Withdrawn
NCT01652079 2018-07-02CRLX101 in Combination With Bevacizumab for Recurrent Ovarian/Tubal/Peritoneal CancerMassachusetts General HospitalPhase 2 Completed63 enrolled